Navigation Links
Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
Date:4/6/2011

PRINCETON, N.J., and OXFORD, England, April 6, 2011 /PRNewswire/ -- BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody dependent cellular cytotoxicity (ADCC) enhanced antibodies.  

OBT intends to use POTELLIGENT® Technology to develop, manufacture and commercialize selected ADCC programs from its pipeline of preclinical antibodies for oncology which it has built based upon novel targets identified using its OGAP® proteomic database.

In return for the license, OBT will pay to BioWa undisclosed license fees, development and commercialization milestones and royalties on sales of any products that it commercializes.

"We are delighted to have access to BioWa's POTELLIGENT® Technology as part of our technology access portfolio as we build a pipeline of first-in-class therapeutic antibodies for cancer," said Christian Rohlff, CEO of OBT.  "Our strategy is to combine novel proprietary oncology targets with world-leading antibody technologies, such as POTELLIGENT® Technology, to develop highly efficacious new cancer drugs for patients with few treatment options."  

"The OBT cancer specific antibody portfolio has matured to an advanced stage where coupling to BioWa's POTELLIGENT® Technology enhances already promising anticancer agents and further enables our clinical development pipeline," commented OBT's Senior Vice President of Oncology, Jon Terrett.

"We are excited to expand our set of small company arrangements with OBT. In large part, our decision to partner with OBT was driven by our interest in novel therapeutic antibody targets identified through the OGAP® proteomic database," said Yasunori Yamaguchi, President and CEO of BioWa.

About POTELLIGENT® Technology

POTELLIGENT®
'/>"/>

SOURCE BioWa, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
2. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
3. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
4. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
5. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
6. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
7. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. CardioVascular BioTherapeutics Submits FDA Application for Fast Track Status for CVBT-141B, CVBTs Biological Treatment for Diabetes Patients
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Top Staten Island Pediatrician Dr. Michael ... which discusses tips for parents about pool safety for children. ... According to US News article, "Drowning is the ... aged 1 to 4, and can occur in as little ... the article says that watching a child in the water ...
(Date:7/23/2014)... July 23, 2014 PositiveID Corp. (OTCQB: PSID), ... , is an emerging player in the bio-threat ... bio-threat detection and rapid medical testing. The Company,s ... Bio-agent Autonomous Networked Detector), was developed under contract ... Science & Technology directorate, and $30 million of ...
(Date:7/23/2014)... Korea , July 23, 2014  Mezzion Pharma ... program to evaluate the use of udenafil to treat ... single ventricle heart defects. The clinical program will follow ... of the Pediatric Heart Network (PHN), a multi-center clinical ... Blood Institute (NHLBI) of the National Institutes of Health ...
Breaking Medicine Technology:Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... KINGSTOWN, R.I., Sept. 7, 2011 Prescription monitoring ... a new comprehensive program, its Safe Use Treatment ... Management, Safe Use is compliant with the FDA,s ... individual State Prescribing Regulations for controlled substances.  The ...
... NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing ... corporate facility located in Laguna Hills, CA.  The ... necessary to begin formal development of its initial ... us a physical presence in Orange County, California ...
Cached Medicine Technology:Dominion Diagnostics Leads Fight Against Prescription Drug Abuse with Safe Use Treatment Monitoring Solution 2NanoSmart™ Pharmaceuticals, Inc., Opens New Headquarters - Begins Development of New Drug Delivery Platform for Cancer 2
(Date:7/23/2014)... checking the pulse of a stroke survivor may help ... the method of choice for checking for irregular heartbeat ... a stroke. Our study shows it may be a ... who might need more thorough monitoring to prevent a ... Erlangen University in Germany. The study included ...
(Date:7/23/2014)... Imaging and Bioengineering will host its second Edward C. ... the NIH campus. There will be ten exciting presentations ... NIBIB-funded research. , WHO: , ... Optical Voltage Sensor, Quyen Nguyen, Univ. of California, ... Imaging during Surgery, Jan Grimm, ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Four hospitals ... been lauded in the latest ranking of the country’s ... . Released online today and slated for publication ... recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint Vincent ... centers across multiple clinical specialties. , “There ...
Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... May 21 This year 28 students in 17 states ... sponsored by the Centers for Disease Control and Prevention and ... invites fifth- and sixth-grade students to create posters that encourage ... and the diseases they can cause. Downloadable files of the ...
... 21 For the second year in a row, the ... blood through the Red Cross by joining Red Cross ... Racing is a program designed to increase the number ... Participants of this program can get points for a variety ...
... quarter of those seeking treatment are addicted to the ... -- More pregnant women in drug treatment programs are ... new research shows. , The number of expectant mothers ... 2006. In 1994, methamphetamine use accounted for 8 percent ...
... "Stem cell research and regenerative medicine are in an ... very fast and many companies are being formed and ... Jonas Frisn. , As an example, a first-in-human study ... drug product, sNN0031, from the Swedish company NeuroNova. The ...
... May 21 Three HealthEast hospitals in the ... the federal government a total of $2.28 million ... Medicare fraud involving a certain type of spinal ... first hospitals to settle charges stemming from a ...
... researchers have found that bipolar disorder is more costly ... or coronary artery disease. These findings are based on ... costs (the costs of seeing any specialist and all ... of this review are being presented today at the ...
Cached Medicine News:Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 2Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 3Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3
... supports interventional cardioangiography procedures with MR imaging ... cardioangiography system., Utilize your angio and MR ... our integrated suite. Because the systems can ... diagnosis and follow-up in one room, one ...
... a comprehensive medical billing software capable ... multiple payer requirements of healthcare billing ... functionality to necessary to process claims ... such as trip reporting for ambulance ...
... code the charge while completing a chart note, ... from office, both directly feeding the charge entry ... Form/Superbill, data entry can be done with our ... are posted by reflecting open item charges, and ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
Medicine Products: